BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/15/2014 6:27:00 PM | Browse: 1234 | Download: 1323
 |
Received |
|
2013-10-20 22:35 |
 |
Peer-Review Started |
|
2013-10-22 15:13 |
 |
To Make the First Decision |
|
2013-12-02 11:45 |
 |
Return for Revision |
|
2013-12-04 21:41 |
 |
Revised |
|
|
 |
Second Decision |
|
2014-01-20 09:49 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2014-01-20 10:08 |
 |
Articles in Press |
|
|
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2014-04-19 13:08 |
 |
Publish the Manuscript Online |
|
2014-04-28 14:14 |
Category |
Cell Biology |
Manuscript Type |
Topic Highlights |
Article Title |
“Ins” and “Outs” of mesenchymal stem cell osteogenesis in regenerative medicine
|
Manuscript Source |
Invited Manuscript |
All Author List |
Dean T Yamaguchi |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
Veterans Administration Merit Review Award |
2 I01 BX000170-05 |
|
Corresponding Author |
Dean T Yamaguchi, MD, PhD, Research Service, Veteran Administration Greater Los Angeles Healthcare System and David Geffen School of Medicine at University of California at Los Angeles, 11301 Wilshire Blvd, Bldg 114, Rm 330, Los Angeles, CA 90073, United States. dean.yamaguchi@va.gov |
Key Words |
Mesenchymal stem cell; Telomerase reverse transcriptase; Extracellular matrix; Osteogenesis; Regenerative medicine; Tissue engineering; Proliferation; Differentiation |
Core Tip |
When human telomerase reverse transcriptase (hTERT) transformed human mesenchymal stem cells (hMSCs) are used to prolong replicative potential and osteogenic differentiation, consideration should be given to using lower population doubling hTERT-transformed hMSCs to avoid potential oncogenesis. An inducible hTERT system may also avoid oncogenic transformation. Demonstration of in vivo bone forming capacity of hTERT-transformed cells should be used as standard in determining osteogenic differentiation of such cells rather than in vitro culture mineralization; the CD146 marker may be a suggested surface marker for hTERT-transformed hMSCs that may have the capacity to form bone in vivo. Native ECM from early population doubling hMSCs or hMSCs from a younger source may be best when seeking to extend the proliferative and differentiating potential of hMSCs from either young or older sources. |
Publish Date |
2014-04-28 14:14 |
Citation |
Yamaguchi DT. “Ins” and “Outs” of mesenchymal stem cell osteogenesis in regenerative medicine. World J Stem Cells 2014; 6(2): 94-110 |
URL |
http://www.wjgnet.com/1948-0210/full/v6/i2/94.htm |
DOI |
http://dx.doi.org/10.4252/wjsc.v6.i2.94 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345